Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19123966 | 0.85 | POLB (0.38) | ALDH1A1TSHRL3MBTL1KDM4EPOLB | |
| SCHEMBL10263887 | 0.82 | CA12 (0.48) | CA12CA7CA14SMN1; SMN2ALDH1A1 | |
| SCHEMBL14605293 | 0.81 | CA1 (0.37) | SMN1; SMN2ALDH1A1TSHRL3MBTL1KDM4E | |
| SCHEMBL30341350 | 0.79 | CA1 (0.41) | SMN1; SMN2ALDH1A1TSHRL3MBTL1KDM4E | |
| SCHEMBL22093201 | 0.79 | CA12 (0.50) | CA12CA7CA14SMN1; SMN2ALDH1A1 | |
| SCHEMBL1107023 | 0.79 | CA12 (0.54) | CA12CA7CA14SMN1; SMN2ALDH1A1 | |
| SCHEMBL19783762 | 0.78 | SMN1; SMN2 (0.37) | SMN1; SMN2ALDH1A1TSHRL3MBTL1KDM4E | |
| SCHEMBL22912674 | 0.76 | CA12 (0.42) | CA12CA7CA14SMN1; SMN2ALDH1A1 | |
| SCHEMBL21795553 | 0.75 | CA12 (0.50) | CA12CA7CA14SMN1; SMN2ALDH1A1 | |
| SCHEMBL2606114 | 0.74 | KDM4E (0.42) | SMN1; SMN2ALDH1A1TSHRL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071316-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | Kineta Immuno-Oncology LLC | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071316-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | RARB, RARG, RARA | CA12 2960/4885CA7 2150/4885CA14 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.